Nerviano (Milano), December 27, 2017 - SARI, a Chinese market-leader biotech investment company, today announced it has entered into an agreement to acquire the 90% interests in Group NMS
Mass spectrometry (MS) performed under native-like conditions (nMS) is a promising approach for studying protein-drug interactions, and has already informed treatments of some of the most intractable diseases including cancer, diabetes and Alzheimer’s.